Clinical trials: Obstructive Pulmonary Disease
Severe Asthma
Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma
This is an open-label, single arm study designed to evaluate the safety of tezepelumab administered subcutaneously every 4 weeks in Japanese adult and adolescent subjects with inadequately controlled severe asthma.
- Trial name
- NOZOMI (NCT04048343)
- Testing
- Biological: Experimental: Tezepelumab
- Where
- 5 sites in Japan
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period.
- Trial name
- NCT01040689
- Testing
- Olodaterol (BI1744) Low, Olodaterol (BI1744) High, Tiotropium 18 mcg
- Where
- 15 sites in Belgium, Denmark and 2 more
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
COPD
A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)
The purpose of the study is to propose that roflumilast is associated with meaningful reductions in biomarkers of pulmonary inflammation and sputum neutrophilia, including confirmation of previously described results, and…
- Trial name
- NCT01572948
- Testing
- roflumilast
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Alabama at Birmingham
Asthma, Lung Diseases
Study of Acid Reflux in Asthma
The purpose of this study is to determine if subjects with symptomatic asthma who are assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer asthma attacks than similar subjects assigned to…
- Conditions
- Asthma, Lung Diseases, Lung Diseases, Obstructive
- Trial name
- NCT00069823
- Testing
- Esomeprazole
- Where
- 20 sites in United States
- Volunteers
- 403 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Asthma
Coordinated Healthcare Interventions for Childhood Asthma Gaps in Outcomes
Chicago is an epicenter for asthma health disparities in the U.S., with African-American children 5-11 yrs bearing a disproportionate share of the burden.
- Trial name
- CHICAGO (NCT02319967)
- Testing
- CAPE, CHW home visits
- Where
- 6 sites in United States
- Volunteers
- 373 people
- Sponsor
- University of Illinois Chicago
Obstructive Sleep Apnea
Effect of Upper Airway Stimulation on Vascular Function in Obstructive Sleep Apnea
This study will evaluate the effect of hypoglossal nerve stimulation (HGNS) on different measures of cardiovascular function in patients with obstructive sleep apnea (OSA).
- Trial name
- NCT03051165
- Testing
- Hypoglossal Nerve Stimulation Treatment Withdrawal
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Emory University
Asthma
Redesigning Ambulatory Care Delivery to Enhance Asthma Control in Children
The investigators have developed a tool to facilitate asthma self-management in children, the electronic-AsthmaTracker (e-AT). The e-AT changes ambulatory asthma care delivery to a new model that is continuous and proactive…
- Trial name
- NCT02409277
- Testing
- Experimental: Standard vs Intensive e-AT Intervention
- Where
- United States
- Volunteers
- 926 people, healthy volunteers welcome
- Sponsor
- University of Utah
Asthma
Sputum-derived Cellular Targets After Xolair (Omalizumab)
The primary purpose of this study is to identify additional mechanisms of action of omalizumab that will lead to improved stratification of patients for treatment.
- Trial name
- NCT02658877
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NYU Langone Health
Chronic Obstructive Pulmonary Disease, Bronchitis
Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate and compare the efficacy of arformoterol twice a day and tiotropium once a day (dosed sequentially) versus tiotropium once a day alone in subjects with Chronic Obstructive Pulmonary…
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
- Trial name
- NCT00424528
- Testing
- Arformoterol Tartrate Inhalation Solution, Tiotropium, Arformoterol and Tiotropium
- Where
- 28 sites in United States
- Volunteers
- 235 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Aclidinium/Formoterol Fixed Combination Dose Finding Study
The study seeks to determine the optimal dose of the Aclidinium/Formoterol combination for investigation in Phase III clinical trials
- Trial name
- NCT00626522
- Testing
- Aclidinium bromide and formoterol
- Where
- 9 sites in Australia, Czechia and 2 more
- Volunteers
- 808 people
- Sponsor
- AstraZeneca
Lung Diseases, Pulmonary Disease, Chronic Obstructive
An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)
This is a study to evaluate the effectiveness and tolerability of a once-daily oral medication (MK-0873) for the treatment of COPD (chronic obstructive pulmonary disease) to determine whether the study drug leads to an…
- Trial name
- NCT00132730
- Testing
- MK-0873 2.5 mg, MK-0873 1.25 mg, MK-0873 0.75 mg
- Volunteers
- 604 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive
Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities
The objective of the present Post Marketing Surveillance Study (PMS) study is to evaluate safety and effectiveness of tiotropium bromide (Spiriva®) 18 µg once daily in 5,000 patients with COPD of varying severities over 8 weeks.
- Trial name
- NCT00621582
- Volunteers
- 4,918 people
- Sponsor
- Boehringer Ingelheim
Acute Asthma
Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study
Our overall objective is to model a pediatric Acute Asthma Clinical Decision Rule (ADR) for personalized medicine by identification of treatment-response phenotypes that are important determinants of outcome.
- Trial name
- OARS (NCT01196377)
- Testing
- Albuterol
- Volunteers
- 16 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Asthma
Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma
This study will evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma.
- Trial name
- TRAILHEAD (NCT04673630)
- Testing
- Tezepelumab
- Where
- 6 sites in Hungary, South Africa and 1 more
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Asthma
A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects
The primary aim of this study is to clarify the position of FF and FF/Vilanterol (VI) 100/25 micrograms (mcg) compared with existing therapies by assessing FF dosage equivalent to low to middle-dose inhaled corticosteroids (ICS).
- Trial name
- NCT02094937
- Testing
- Fluticasone Furoate/Vilanterol, Fluticasone Furoate 100 mcg, Fluticasone Propionate 250 mcg
- Where
- 33 sites in Japan
- Volunteers
- 430 people
- Sponsor
- GlaxoSmithKline
Asthma
Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma
Study D9181C00001 is a Phase II, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of MEDI3506 in adult participants…
- Trial name
- FRONTIER-3 (NCT04570657)
- Testing
- MEDI3506
- Where
- 65 sites in United States, Argentina and 5 more
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Asthma
Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate in Asthmatic Patients (Study P04879)(TERMINATED)
Open label, 12-week clinical trial to assess efficacy, safety, treatment adherence and Quality of Life impact of Mometasone Furoate dry powder 400 mcg once-daily in persistent mild-moderate asthmatic patients at least 12 years…
- Trial name
- APEGO (NCT00687531)
- Testing
- Mometasone Furoate
- Volunteers
- 385 people
- Sponsor
- Organon and Co
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the safety and efficacy of indacaterol 150 µg taken once daily (o.d.) versus salmeterol 50 µg taken twice daily (b.i.d) in patients 40 years old or older with chronic obstructive pulmonary disease.
- Trial name
- INSIST (NCT00821093)
- Testing
- Indacaterol 150 µg, Salmeterol 50 µg
- Where
- 144 sites in United States, Czechia and 6 more
- Volunteers
- 1,123 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
- Trial name
- SOURCE (NCT03406078)
- Testing
- Tezepelumab
- Where
- 60 sites in United States, Argentina and 5 more
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.